Clinical trial
Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis
NCT00172003 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00172003 |
|---|---|
| Title | Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis |
| Official title | Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Renal Cell Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Zoledronic acid |
| Enrollment | 50 |
| Start date | Sep 1, 2004 |
| Primary completion | Jul 1, 2009 |
| Completion | Jul 1, 2009 |
| First posted | Sep 15, 2005 |
| Last update posted | Nov 18, 2016 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: